Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent
Authors Hedgire S, McDermott S, Wojtkiewicz G, Abtahi SM, Harisinghani M, Gaglia J
Received 28 January 2014
Accepted for publication 15 March 2014
Published 28 April 2014 Volume 2014:9(1) Pages 2101—2107
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Sandeep S Hedgire,1 Shaunagh McDermott,1 Gregory R Wojtkiewicz,1 Seyed Mahdi Abtahi,1 Mukesh Harisinghani,1 Jason L Gaglia2
1Center for Systems Biology, Massachusetts General Hospital, Richard B Simches Research Center, 2Joslin Diabetes Center, Boston, MA, USA
Purpose: To evaluate the time-dependent changes in regional quantitative T2* maps of the kidney following intravenous administration of ferumoxytol.
Materials and methods: Twenty-four individuals with normal kidney function underwent T2*-weighted MRI of the kidney before, immediately after, and 48 hours after intravenous administration of ferumoxytol at a dose of 4 mg/kg (group A, n=12) or 6 mg/kg (group B, n=12). T2* values were statistically analyzed using two-tailed paired t-tests.
Results: In group A, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.3% and 64.2% for the cortex and 90.8% and 64.6% for the medulla, respectively. In group B, the percentage changes from baseline to immediate post and baseline to 48 hours were 85.2% and 73.4% for the cortex and 94.5% and 74% for the medulla, respectively. This difference was significant for both groups (P<0.0001).
Conclusion: There is significant and differential uptake of ferumoxytol in the cortex and medulla of physiologically normal kidneys. This differential uptake may offer the ability to interrogate renal cortex and medulla with possible clinical applications in medical renal disease and transplant organ assessment. We propose an organ of interest based dose titration of ferumoxytol to better differentiate circulating from intracellular ferumoxytol particles.
Keywords: USPIO, ferumoxytol, renal MRI, T2* weighted imaging
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]